Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC3153 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7853.042 | 0.9785 | 0.9755 | 1.7624 | |
| HCC3153 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7853.042 | 0.9706 | 0.9664 | 1.7624 | |
| HCC3153 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.137 | uM | 7853.042 | 0.7639 | 0.7166 | 1.7624 | |
| HCC3153 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.685 | uM | 7853.042 | 0.8679 | 0.8456 | 1.7624 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7854.018 | 0.9524 | 0.9222 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 7854.018 | 0.9806 | 0.9683 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 7854.018 | 0.8003 | 0.6687 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 7854.018 | 0.9881 | 0.9806 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 7854.018 | 0.9516 | 0.9209 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 7854.018 | 0.9299 | 0.8852 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 7854.018 | 0.9325 | 0.8895 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 7854.018 | 0.9736 | 0.9569 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 7854.018 | 0.8666 | 0.7802 | 1.2298 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9028.018 | 0.8991 | 0.8027 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9028.018 | 1.1133 | 1.2209 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9028.018 | 0.9094 | 0.8229 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9028.018 | 0.9940 | 0.9883 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9028.018 | 0.9787 | 0.9583 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9028.018 | 0.9961 | 0.9923 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9028.018 | 0.9736 | 0.9484 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9028.018 | 1.0051 | 1.0099 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9028.018 | 0.9270 | 0.8573 | 1.0242 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9453.125 | 1.0034 | 1.0055 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9453.125 | 1.0165 | 1.0266 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9453.125 | 1.0210 | 1.0340 | 1.2351 |